TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06063616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Level I Reiki was applied to 9 points and nearby areas for 30 minutes, three sessions a week, for a total of four weeks, in the first three hours of the HD treatment, by the researcher, who completed his second level training according to the Usui method, in line with the Reiki/Sham Reiki Application Protocol.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Reiki
Description: Sham Reiki was applied to 9 points and nearby areas in accordance with the Reiki/Sham Reiki Application Protocol, for a total of four weeks, three sessions per week, for 30 minutes, in the first three hours of the HD treatment, by two students who had not received Reiki training, and were given training on the application by the researcher.
Study: NCT05006677

Intervention type: DRUG
Intervention: non-vitamin K antagonist oral anticoagulants (NOACs)
Description: Collecting information of patients with VT who received NOACs

Intervention type: DRUG
Intervention: vitamin K antagonists (VKAs)
Description: Collecting information of patients with VT who received VKAs

Intervention type: DRUG
Intervention: antiplatelet agents
Description: Collecting information of patients with VT who received antiplatelet agents

Intervention type: OTHER
Intervention: non-antithrombotic therapy
Description: Collecting information of patients with VT without any antithrombotic therapy
Study: NCT05838274

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol vs. Placebo beverage conditions
Description: Individuals will drink beverages containing alcohol. How they respond to a high vs. low dose will be compared.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol vs. Placebo beverage conditions
Description: Individuals will drink beverages containing alcohol. How they respond to a high vs. low dose will be compared.
Study: NCT05768958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 45 min exercise bout performed on bicycle ergometer. The exercise bout will consist of a 10 min warm-up period at 40 % Watt max followed by 4 cycles of 4 min at 85 % Watt max and 3 min at 50 % Watt max. A cool-down period (7 min) will be performed at 40 % Watt max.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 45 min exercise bout performed on bicycle ergometer. The exercise bout will consist of a 10 min warm-up period at 40 % Watt max followed by 4 cycles of 4 min at 85 % Watt max and 3 min at 50 % Watt max. A cool-down period (7 min) will be performed at 40 % Watt max.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: 45 min rest during the same time period as the exercise bout on exercise study visits.
Study: NCT05043688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: iCamrelizumab combined with neoadjuvant chemotherapy; Camrelizumab combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: iCamrelizumab combined with neoadjuvant chemotherapy; Camrelizumab combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: iCamrelizumab combined with neoadjuvant chemotherapy; Camrelizumab combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.
Study: NCT05768958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: 45 min rest during the same time period as the exercise bout on exercise study visits.
Study: NCT06568016

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive clinical care consistent with current practice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive clinical care consistent with current practice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Communication Intervention
Description: Receive standardized communication from FIT QI champion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Receive standardized communication from FIT QI champion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Receive coordination from GI liaisons

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordination
Description: Receive enhanced GI care coordination

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Watch pre-colonoscopy educational video

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Undergo FIT result review by Primary Care FIT Tracker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Undergo FIT result review by Primary Care FIT Tracker

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Undergo generation and review of GI FIT Tracker report

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive informational sheet
Study: NCT06122870

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CampETEC HBC product
Description: Immunoglobulin from bovine milk/colostrum and challenge strain

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ProMilk 85
Description: Placebo ProMilk 85
Study: NCT06568016

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies
Study: NCT06122870

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. jejuni CG8421 Challenge strain
Description: Challenge strain C. jejuni CG8421

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: C. jejuni CG8421 Challenge strain
Description: Challenge strain C. jejuni CG8421
Study: NCT05715242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Behavioral Weight Loss Intervention
Description: All participants will receive a 10-week core behavioral weight loss treatment consisting of: self-monitoring weight, steps, and food intake; behavioral lessons; action plans; and tailored feedback. The intervention will be delivered remotely via email and digital tools (such as a smart scale, Fitbit activity tracker, and Fitbit app).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Behavioral Weight Loss Intervention
Description: All participants will receive a 10-week core behavioral weight loss treatment consisting of: self-monitoring weight, steps, and food intake; behavioral lessons; action plans; and tailored feedback. The intervention will be delivered remotely via email and digital tools (such as a smart scale, Fitbit activity tracker, and Fitbit app).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Behavioral Weight Loss Intervention
Description: All participants will receive a 10-week core behavioral weight loss treatment consisting of: self-monitoring weight, steps, and food intake; behavioral lessons; action plans; and tailored feedback. The intervention will be delivered remotely via email and digital tools (such as a smart scale, Fitbit activity tracker, and Fitbit app).
Study: NCT06568016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Receive navigation from GI liaisons

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral
Description: Receive referral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral
Description: Receive referral per standardized template

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message-Based Navigation Intervention
Description: Receive follow-up text message
Study: NCT06445153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention with clinical decision support system
Description: To this phase, patient data is automated and systematically analyzed in order to derive decision support based on current evidence and make it available to Digi-POD users (patients, relatives, nursing staff, doctors, other healthcare professionals).
Study: NCT06198296

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: 21.15.GPC3-CAR T cells
Description: Three different dosing schedules will be evaluated.~The following dose levels will be evaluated:~The following dose levels will be evaluated:~DL0: 3x10\^7/m2 DL1: 1x10\^8/m2 DL2: 3x10\^8/m2 DL3: 1x10\^9/m2
Study: NCT05661552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 MG/ML
Description: Randomly assigned Evolocumab + rosuvastatin + ezetimibe versus rosuvastatin + ezetimibe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5mg
Description: Rosuvastatin 5mg will be assigned to all participants

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 5mg
Description: Rosuvastatin 5mg will be assigned to all participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg
Description: Ezetimibe 10mg will be assigned to all participants

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10mg
Description: Ezetimibe 10mg will be assigned to all participants
Study: NCT05715242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Behavioral Weight Loss Intervention
Description: All participants will receive a 10-week core behavioral weight loss treatment consisting of: self-monitoring weight, steps, and food intake; behavioral lessons; action plans; and tailored feedback. The intervention will be delivered remotely via email and digital tools (such as a smart scale, Fitbit activity tracker, and Fitbit app).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Behavioral Weight Loss Intervention
Description: All participants will receive a 10-week core behavioral weight loss treatment consisting of: self-monitoring weight, steps, and food intake; behavioral lessons; action plans; and tailored feedback. The intervention will be delivered remotely via email and digital tools (such as a smart scale, Fitbit activity tracker, and Fitbit app).
Study: NCT05486871

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic partial nephrectomy
Description: This is a prospective non- randomized controlled study of patients with RCC Who will be referred to urology department, Sohag university hospital. Our comparative study contained two groups according to tumor stage at preoperative contrast study:~Group \[A\] : 15 patients with T1 RCC (≤ 7 cm). Group \[B\] : 15 patients with T2a RCC (≤ 10 cm). the patients will be subjected to laparoscopic partial nephrectomy then will be followed up for two years for oncological and functional outcomes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic partial nephrectomy
Description: This is a prospective non- randomized controlled study of patients with RCC Who will be referred to urology department, Sohag university hospital. Our comparative study contained two groups according to tumor stage at preoperative contrast study:~Group \[A\] : 15 patients with T1 RCC (≤ 7 cm). Group \[B\] : 15 patients with T2a RCC (≤ 10 cm). the patients will be subjected to laparoscopic partial nephrectomy then will be followed up for two years for oncological and functional outcomes.
Study: NCT06415747

Intervention type: OTHER
Intervention: Observational pain and motor function assessments, and also comorbidities assessments with x-ray.
Description: There was no intervention in our study, only observational and quantitative clinical evaluations.
Study: NCT04965090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab 1050mg IV once weekly for the first 28 days (Cycle 1) and every other week thereafter. For subjects who weigh ≥80 kg, they will receive 350mg IV on C1D1 and 1050 mg on C1D2. They will continue to receive amivantamab 1400 IV once weekly for the first 28 days and every other week thereafter. Each cycle is 28 days in length.
Study: NCT06139406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-87801493
Description: JNJ-87801493 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-87801493
Description: JNJ-87801493 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-80948543
Description: JNJ-80948543 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-80948543
Description: JNJ-80948543 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-75348780
Description: JNJ-75348780 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-75348780
Description: JNJ-75348780 will be administered subcutaneously.
Study: NCT04747496

Intervention type: DRUG
Intervention: Edoxaban
Description: This is a non-interventional, observational study.
Study: NCT05244889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital CBT-I
Description: The digital CBT-I intervention (www.sleepio.com) consists of six weekly sessions of CBT-I delivered over the internet by an animated virtual therapist known as The Prof. The content includes behavioral (e.g. sleep restriction, stimulus control), cognitive (e.g. putting the day to rest, thought re-structuring, mindfulness) strategies, relaxation strategies (e.g., progressive muscle relaxation) and advice on lifestyle and bedroom factors (sleep hygiene). Although the sessions can be completed at the persons own pace, the shortest interval between individual sessions is 7 days, thus participants can complete the course in 6 weeks, or take as long as 12 weeks. As part of the SLEEPIO program, participants will be required to enter their sleep/wake patterns using electronic sleep diaries. There is no face-to-face contact throughout the intervention and all treatment sessions, support and reminders are provided through the online platform.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Education
Description: Sleep Hygiene Education (SHE) has successfully been used as a control condition in other trials evaluating dCBT-I42. SHE does not have any therapeutic benefits for individuals with insomnia alone, but is often part of usual care. Consequently it is a credible alternative to dCBT-I. The sleep hygiene education will be provided on a website with access to information about lifestyle changes (e.g., reducing exercise in the evening, light snack before bedtime, reducing caffeine) and changes to the bedroom environment (e.g., dark room, comfortable mattress, optimal room temperature). As with the dCBT-I group, participants will not be required to make any changes to their usual care.
Study: NCT05160584

Intervention type: OTHER
Intervention: No intervention
Description: There is no interventional treatment component for participants with RRMM in this study.
Study: NCT06500884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talquetamab
Description: Talquetamab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylaxis A
Description: Prophylaxis A will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylaxis B
Description: Prophylaxis B will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylaxis C
Description: Prophylaxis C will be administered orally.
Study: NCT06045273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elders' Resilience Curriculum
Description: The Elders' Resilience Curriculum (ERC) is a culturally grounded, school-based program taught by White Mountain Apache Tribe (WMAT) Elders to youth. It is designed to prevent suicide ideation and behaviors for American Indian youth
Study: NCT06518785

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Focused Ultrasound
Description: An inhibitory LIFU protocol that allows suppression of neuronal activity in the basal ganglia and thalamus will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Intensity Focused Ultrasound
Description: An inhibitory LIFU protocol that allows suppression of neuronal activity in the basal ganglia and thalamus will be used.
Study: NCT05715242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Easier Step Goal
Description: Participants will receive an easier daily step goal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Easier Step Goal
Description: Participants will receive an easier daily step goal.
Study: NCT06466109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social robot intervention
Description: In the first and second courses, the patients and their parents freely interact with the social robot PARO for 30 minutes.~In the third course, patients and their parents interact with PARO for 30 minutes using a worksheet that includes naming and recording characteristics of PARO.~In the last course, patients and their parents interact with PARO for 30 minutes using a worksheet that freely recorded their observations about PARO and say goodbye to it.
Study: NCT05575492

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1647
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1647
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1647
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1647
Description: Sterile liquid for injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride injection (normal saline)
Study: NCT05225935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: image-guided VT ablation strategy
Description: Catheter ablation procedure performed as part of standard care, although with the addition of an image-based 3D heart model including detailed anatomy and primary ablation targets

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional VT ablation strategy
Description: Catheter ablation will be performed using conventional mapping techniques to identify targets. The ablation strategy will be left to the local investigator's decision, based on the clinical scenario and operator's habits.
Study: NCT04751929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Taken orally 2x daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Taken orally 2x daily
Study: NCT05882305

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous monocyte-derived DCs pulsed withEBV-associated antigen
Description: Patients will receive approximately （2.5-10）x10\^6 DC vaccine via subcutaneous injections bi-weekly,totally 3-5 times.
Study: NCT05827042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous thrombolysis
Description: Patients will receive intravenous alteplase (0.9mg/kg, maximum 90mg) or tenecteplase (0.25mg/kg, maximum 25mg) before endovascular thrombectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Description: Endovascular thrombectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular thrombectomy
Description: Endovascular thrombectomy
Study: NCT04678232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Processes and Transition to Health (PATH)
Description: See arm/group description for details regarding this intervention
Study: NCT05727761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone-metformin
Description: Treatment with pioglitazone-metformin (15mg/500mg) twice a day for 12 weeks
Study: NCT06122012

Intervention type: DRUG
Group type: OTHER
Intervention: HSK16149 20mg BID
Description: HSK16149 20mg BID with L-carnitine hydrochloride tablets 2 tablets TID ；Lipoic acid tablets 2 tablets BID with L-carnitine hydrochloride tablets 2 tablets TID；

Intervention type: DRUG
Group type: OTHER
Intervention: HSK16149 20mg BID
Description: HSK16149 20mg BID with L-carnitine hydrochloride tablets 2 tablets TID ；Lipoic acid tablets 2 tablets BID with L-carnitine hydrochloride tablets 2 tablets TID；
Study: NCT05420298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical mobilization
Description: All participants will receive only single session of cervical mobilization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cervical manipulation
Description: All participants will receive only single session of cervical manipulation
Study: NCT04173975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: With knee exoskeleton
Description: BELK is a wearable system that assists when and where the patient needs it intelligently through proper control of the system and optimized gait assistance techniques. Assisted-as-needed control allows to create a force field along a desired trajectory, proportionally applying torque only when patient deviates from the pre-programmed correct pattern. This force field control, by assisting only the segments that the patient need, produces a natural gait pattern, improving the rehabilitation process.
Study: NCT04751929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Taken orally 2x daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenously Day 1 of 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenously Day 1 of 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenously Day 1 of 21 day cycle